Summary by Futu AI
Cingulate Inc., a biopharmaceutical company, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on August 19, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the potential sale of up to 1,000,000 shares of common stock by Lincoln Park Capital Fund, LLC (Lincoln Park), a selling stockholder. The shares may be sold from time to time in various types of transactions, including ordinary broker transactions and direct sales. The registration allows for the sale of these shares by Lincoln Park at market prices or at negotiated prices. Cingulate Inc. will not receive any proceeds from the sale of shares by Lincoln Park. The company has previously entered into a Purchase Agreement with Lincoln Park, which allows Cingulate to direct Lincoln Park to purchase up to $12 million of its common stock, subject to certain conditions and limitations. As of the filing date, Cingulate's common stock and warrants are listed on the Nasdaq under the symbols 'CING' and 'CINGW' respectively.
